MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab

Br J Dermatol. 2018 Sep;179(3):787-789. doi: 10.1111/bjd.16659. Epub 2018 Aug 20.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adalimumab / pharmacology
  • Adalimumab / therapeutic use*
  • Adult
  • Aged
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Case-Control Studies
  • Epigenesis, Genetic / drug effects
  • Feasibility Studies
  • Female
  • Healthy Volunteers
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • Male
  • MicroRNAs / blood*
  • MicroRNAs / metabolism
  • Middle Aged
  • Psoriasis / blood
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Skin / drug effects
  • Skin / pathology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Young Adult

Substances

  • Biomarkers
  • MIRN146 microRNA, human
  • MicroRNAs
  • TNF protein, human
  • Tumor Necrosis Factor-alpha
  • Adalimumab